抗中性粒细胞胞浆抗体相关性血管炎的临床研究进展

Key advances in the clinical studies of ANCA-associated vasculitis

抗中性粒细胞胞浆抗体相关性血管炎[anti-neutrophil cytoplasmic antibodies(ANCA)-associated vasculitis,AAV]临床表现多种多样,故治疗方案也不尽相同。目前AAV仍没有确定的诊断标准和统一的治疗指南。临床处理AAV患者时需要从疾病分期、疾病活动和(慢性)损害的区别和生活质量3个方面进行评估。文中就血管炎最新分类、疾病分期和严重性的关系、活动性和永久性损害之间区别的重要性、治疗方案的选择以及合并症的处理进行综述。

Anti-neutrophil cytoplasmic antibodies（ ANCA）-associated vasculitis（ AAV） has various clinical symptoms,thus various treatment schemes were used in clinics. To date,there has been no validated diagnostic criteria or treatment guideline for AAV. There are three aspects to be considered when assessing the treatment with AAV patients： staging of disease,distinction between disease activity and chronic damages,and quality of life（ QOL）. This review focuses on the latest classification of vasculitis,the relation between disease stages and its severity,the importance of distinguishing active diseases from permanent damages,the therapeutic choices and the management of complications.